NRTIS AND PENTAMIDINE
Additive pancreatic toxicity has occurred with the concurrent use of zalcitabine and intravenous pentamidine, and a similar interaction is expected with didanosine or stavudine. Didanosine, stavudine and zalcitabine alone have all been associated with fatal pancreatitis.
The manufacturers of zalcitabine recommend that if pentamidine is needed, treatment with zalcitabine should be interrupted. A similar recommendation has been made for didanosine, although the manufacturers suggest that close monitoring is adequate. Careful monitoring is recommended if pentamidine is given with stavudine.
The manufacturers of zalcitabine recommend that if pentamidine is needed, treatment with zalcitabine should be interrupted. A similar recommendation has been made for didanosine, although the manufacturers suggest that close monitoring is adequate. Careful monitoring is recommended if pentamidine is given with stavudine.